Metaphyseal sclerosis in a child with a giant cell tumour treated with denosumab

Lancet. 2023 Jul 15;402(10397):e4. doi: 10.1016/S0140-6736(23)00915-7.

Authors

Vivian Szymczuk¹, Alison Boyce², Nadia Merchant³

Affiliations

¹ Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA. Electronic address: vivian.szymczuk@nih.gov.
² Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.
³ Children's National Medical Center, Washington, DC, USA.

PMID: 37453752
DOI: 10.1016/S0140-6736(23)00915-7

No abstract available

MeSH terms

Bone Density Conservation Agents* / therapeutic use
Bone Neoplasms* / diagnostic imaging
Bone Neoplasms* / drug therapy
Child
Denosumab / therapeutic use
Giant Cell Tumor of Bone* / diagnostic imaging
Giant Cell Tumor of Bone* / drug therapy
Giant Cell Tumor of Bone* / pathology
Giant Cell Tumors*
Humans
Sclerosis

Substances

Denosumab
Bone Density Conservation Agents